Objectives. The main goal of this work was to analyse how treatment intervention with tofacitinib prevents the early disturbances of bone structure and mechanics in the rat model of adjuvant-induced arthritis. This is the first study to access the impact of tofacitinib on the skeletal bone effects of inflammation.
Introduction
RA is a chronic immune-mediated inflammatory disease, which affects $1% of the world population [1] . RA is associated with an increased expression of the RANK ligand (RANKL) and low levels of its antagonist, osteoprotegerin (OPG) [2] . RANKL is a crucial activator of osteoclastogenesis [3] . In addition, RA serum and synovial fluid (SF) present an inflammatory cytokine profile, including IL1b, IL-6, IL-17 and TNF, which further favours osteoclast differentiation and activation, starting in the early phase of the disease [46] . Evidence suggests that an imbalance in bone remodelling in RA contributes not only to local bone erosions but also to the development of systemic osteoporosis [7] and increased rates of vertebral and hip fractures in these patients [8, 9] .
Tofacitinib is a selective inhibitor of Janus kinase 1 (JAK1) and Janus kinase 3 (JAK 3), thus interfering with the dimerization of signal transducer and activator of transcription (STAT) molecules, blocking the activation of gene transcription that is dependent on the JAKSTAT signalling pathway [1012] . Tofacitinib has been recently approved by the European Medicines Agency for the indication of RA treatment [13] . The main goal of this work was to analyse whether treatment intervention with tofacitinib in the rat model of adjuvant-induced arthritis (AIA) prevents the early disturbances of bone structure and strength induced by inflammation.
Methods

Animals and experimental design
Fifty 8-week-old female Wistar AIA rats weighing $200 g were housed in European type II standard filter top cages (Tecniplast, Buguggiate, Italy) and transferred into the specific pathogen-free animal facility at the Instituto de Medicina Molecular, Lisboa, Portugal. The AIA rats were purchased from Charles River Laboratories international (Barcelona, Spain).
Sample size was calculated using the Power Analysis statistical test from the G*Power 3.1 software [14] . The test was based on our own previous data [15] , comparing the medians of the experimental groups using the MannWhitney U-test, with a (probability of error) = 0.05, power = 95%, effect size = 1.751632 and actual power = 0.95072 [16] .
Upon arrival, animals were individually identified and randomly housed in experimental groups, as follows: non-arthritic healthy group (n = 20); arthritic rats treated with tofacitinib (10 mg/kg body weight, by oral gavage, twice a week; n = 10); and arthritic rats not treated (received an equal volume of vehicle, 0.5% methylcellulose in water; n = 20). Tofacitinib administration was started 4 days after disease induction, when animals already presented clinical signs of arthritis. The inflammatory score, ankle perimeter and body weight were measured during the period of treatment. Inflammatory signs were evaluated by counting the score of each joint on a scale of 03 (0: absence; 1: erythema; 2: erythema and swelling; 3: deformities and functional impairment). The total score of each animal was defined as the sum of the partial scores of each affected joint. Rats were killed 22 days after induction of disease, because maximal disease activity and severity occurs at day 19, plateaus up to day 22 after disease induction, and thereafter the inflammatory signs disappear [17] . Blood, paws and bone samples were collected.
Experiments were approved by the Animal User and Ethical Committees, at the Instituto de Medicina Molecular (Lisbon University), according to Portuguese law and European recommendations.
Histological evaluation of hind paws
Left hind paw samples collected at the time of sacrifice were fixed immediately in 10% neutral buffered formalin solution and then decalcified in 10% formic acid. Samples were then dehydrated, embedded in paraffin, and serially sectioned at a thickness of 5 mm. Sections were stained with Haematoxylin and Eosin for histopathological evaluation of structural changes and cellular infiltration. This evaluation was performed in a blinded fashion using five semi-quantitative scores, as follows: sublining layer infiltration score (0: none to diffuse infiltration; 1: lymphoid cell aggregate; 2: lymphoid follicles; 3: lymphoid follicles with germinal centre formation); lining layer cell number score (0: fewer than three layers; 1: three to four layers; 2: five to six layers; 3: more than six layers); bone erosion score (0: no erosions; 1: minimal; 2: mild; 3: moderate; 4: severe); cartilage surface (0: normal; 1: irregular; 2: clefts; 3: clefts to bone); and global severity score (0: no signs of inflammation; 1: mild; 2: moderate; 3: severe). [18] Immunohistochemical staining of osteocalcin-positive cells in hind paws
Immunolocalization of osteoblasts was performed by staining with osteocalcin primary antibody (Abcam, Cambridge, UK) followed by EnVision+ (Dako, Glostrup, Denmark). Colour was developed by a solution containing diaminobenzadine tetrahydrochloride (Sigma, Missouri, USA), 0.5% H 2 O 2 in phosphate buffer. Slides were counterstained with Haematoxylin and mounted. Immunohistochemical evaluation of rat joints was performed in a blinded fashion using a semi-quantitative score of 03 (0: 025% staining; 1: 2650% staining; 2: 5175% staining; 3: >75% staining) [19] . Histological and imunohistochemical images were acquired using a Leica DM2500 microscope (Leica Microsystems, Wetzlar, Germany) equipped with a colour camera.
STAT1 and suppressor of cytokine signalling 1 expression in bone Expression of STAT1 and suppressor of cytokine signalling 1 (SOCS1) was quantified by quantitative PCR in bone tissue (tibia) from untreated (n = 14) and tofacitinib-treated rats (n = 10). Tibiae were collected after the rats were killed and stored at À80 C. On top of dry ice, each frozen tibia was quickly pulverized with a mortar and pestle, which was previously cooled with liquid nitrogen to maintain a very low temperature and prevent RNA degradation. After pulverization, 2 ml of Trizol reagent (Invitrogen, Carlsbad, CA, USA) was added to the powder, preformed following the manufacturer's instructions.
For quantitative PCR analysis, 1. Quantification of bone remodelling and inflammatory markers Serum samples were collected at sacrifice and stored at À80 C. Bone remodelling markers, carboxy-terminal telopeptide of type I collagen (CTX-I) and procollagen type I propeptides (P1NP), were quantified by Serum Rat Laps ELISA assay (Immunodiagnostic Systems Ltd, Boldon, UK).
The pro-inflammatory cytokines IL-1b, IL-6 (Boster Bio, California, USA), IL-17, OPG, RANKL (Sunred Biological Technology, Shangai, China) and TNF (RayBiotech, Georgia, USA) were quantified in serum samples using specific rat ELISA kits.
Standard curves were generated by using reference biomarker concentrations. Samples were analysed using a plate reader (Infinite M200; Tecan, Mannedorf, Switzerland).
Micro-CT analysis
Structural properties of the trabecular and cortical tibiae were determined with a high-resolution micro-CT system (SkyScan 1272; Bruker microCT, Kontich, Belgium). Moist bones were wrapped in parafilm and covered with dental wax to prevent drying and movement during the scanning. The X-ray tube was set to 50 kV, and the beam was filtered with a 0.5 mm aluminium filter. The sample position and camera settings were adjusted to provide a 3.0 mm isotropic pixel size, and projection images were collected every 0.2 . Tissue mineral density values were calibrated against hydroxyapatite phantoms with densities of 250 and 750 mg/cm 3 . Reconstructions were done with NRecon (v 1.6.9.8; Bruker micro-CT), where appropriate corrections to reduce beam hardening and ring artefacts were applied. Bone was segmented in slices of 3 mm thickness. After 200 slices from the growth plate, we selected and analysed 1400 slices of trabecular bone. For cortical bone, 300 slices (1800 slices from the growth plate) were analysed. Analyses were performed in agreement with guidelines for assessment of bone microstructure in rodents using micro-CT [20] . Trabecular bone morphology was analysed by applying global threshold and despeckle to provide binary image for three-dimensional analyses.
Bone mechanical tests
Femurs were subjected to a three-point bending test using a universal materials testing machine (Instron 3366; Instron Corp., Massachusetts, USA). Femurs were placed horizontally, anterior side upward, on a support with span length of 5 mm. The load was applied with a constant speed of 0.005 mm/s until failure occurred. Stiffness was analysed by fitting a first-degree polynomial function to the linear part of the recorded load deformation data. A displacement of 0.15 mm between the fitted slope and the measured curve was used as the criterion for the yield point, whereas the breaking point was defined as set where force reached maximal value. Force, deformation and absorbed energy were defined both at yield and at the breaking point.
Nanoindentation
Nanoindentation was performed using a CSM-Nano Hardness Tester System (Indentation v.3.83; CSM Instruments SA, Peseux, Switzerland) equipped with a Berkovich diamond tip. After micro-CT, 0.5 mm was cut off the top of the tibia, and the proximal part was embedded in low-viscosity epoxy resin (EpoThin; Buehler, Knorring Oy Ab, Helsinki, Finland). A slow-speed diamond saw was used to remove 10% of the bone length. The sample surface was polished using silicon carbide sandpaper with a decreasing grid size (800, 1200, 2400 and 4800) and finished with a cloth containing 0.05 mm g-alumina particles. The indentation protocol was adopted from previous work [21] , and on average, eight indentations were made on both cortical and trabecular bone with a quasi-static loading protocol. All indentations were performed under an optical microscope to achieve the precise location of indentations at the centre of the targeted area in the tissue [22] .
A trapezoidal loading waveform was applied with a loadingunloading rate of 20 mN/min and with an intermediate load-hold phase lasting 30 s hold at a maximal load 10 mN. The hardness (H IT ), indentation modulus (E IT ), indentation creep (C IT ) and elastic part of indentation work (Z IT ) were measured by using the method of Oliver and Pharr (1992) [23] .
Histological images of rat tibiae from the diaphyseal cortical region were acquired during the nanoindentation technique.
A histological score was applied in order to evaluate the lamellar structures of bone tissue (lamellar bone structure: 1: predominantly parallel lamellae (PL); 2: concentric and PL in the same proportion; 3: predominantly concentric lamellae).
The ratio of osteocyte lacuna area/total tissue area was also evaluated at Â200 magnification in order to analyse the percentage of the total tissue area occupied by osteocyte lacunae. The acquisition method and analysis used were the same as those applied for the evaluation of bone volume/tissue volume in the histomorphometry technique [15] . All variables were expressed and calculated according to the recommendations of the American Society for Bone and Mineral Research [24] , using a morphometric program (Image J 1.46 R with plugin Bone J, Bethesda, Maryland, USA).
Statistical analysis
Statistical differences were determined with the MannWhitney U-test using GraphPad Prism (GraphPad, San Diego, CA, USA). Data were expressed as the median with interquartile range. Differences were considered statistically significant for P < 0.05.
Results
Tofacitinib effectively reduced inflammation in the AIA rat model of arthritis Results showed that tofacitinib effectively controlled and abrogated disease development in comparison with untreated arthritic rats (Fig.1A) . Moreover, untreated arthritic animals sharply increased the ankle perimeter throughout disease progression, which did not occur in tofacitinibtreated animals (Fig.1B) .
Tofacitinib abrogated local joint inflammation and local bone and cartilage damage in AIA rats
The sublining layer infiltration ( Fig. 2A and B) and the number of lining layer cells (Fig. 2C) were lower in the tofacitinib group when compared with the untreated arthritic group at the end of the study (P < 0.0001). Tofacitinib was also effective in preventing joint bone erosions (Fig. 2D ) and cartilage damage ( Fig. 2E ; P < 0.0001 and P = 0.0001 tofacitinib group vs arthritic rats, respectively). Tofacitinib was able to diminish inflammation and local   FIG. 1 Inflammatory score and ankle perimeter (A) Inflammatory score. The tofacitinib group was compared with the vehicle group (arthritic). Results showed statistical differences throughout time from day 10 (P = 0.0071) until day 22 (P = 0.0058). (B) Ankle perimeter. The tofacitinib group was compared with the vehicle group (arthritic). Results showed statistical differences throughout time from day 11 (P = 0.0057) until day 22 (P = 0.0056). Statistical differences were determined with the non-parametric MannWhitney U-test using GraphPad Prism (GraphPad, San Diego, CA, USA). Differences were considered statistically significant for P 4 0.05. Healthy: n = 20; arthritic: n = 20; tofacitinib: n = 10. bone damage significantly ( Fig. 2F ; P < 0.0001 tofacitinib group vs arthritic rats).
In addition, arthritic rats showed increased numbers of osteoblasts in the hind paw (P = 0.0029 vs healthy controls). Tofacitinib administration significantly lowered the number of osteoblasts to levels similar to those of healthy controls (P = 0.0035 vs arthritic rats; supplementary Fig. S1 , available at Rheumatology Online).
Tofacitinib downregulates the JAKSTAT pathway in bone tissue
A significantly decreased expression of STAT1 (supplementary Fig. S2A , available at Rheumatology Online) and SOCS1 (supplementary Fig. 2B , available at Rheumatology Online) was observed in the bone of AIA rats treated with tofacitinib, in comparison with arthritic untreated rats (P = 0.0019 and P = 0.044, respectively).
Tofacitinib reduced bone remodelling and inflammatory markers
We observed that both CTX-I (Fig. 3A) and P1NP (Fig. 3B) were significantly increased in the arthritic group in comparison with the healthy control animals (P < 0.0001 and P = 0.0015, respectively). The tofacitinib group showed decreased values for CTX-I (P = 0.0002) and P1NP (P = 0.0018) when compared with the arthritic group (Fig. 3) .
RANKL levels were decreased in the serum of tofacitinib-treated rats in comparison with healthy control and untreated arthritic rats (P = 0.0083 and P = 0.0141, respectively), as observed in Fig 3C. OPG levels were also reduced in the tofacitinib group in comparison with healthy controls and untreated arthritic rats (P = 0.0031 and P = 0.0002, respectively; Fig. 3D ). No differences were observed in the RANKL/OPG ratio between the FIG. 2 Inflammatory and structural score applied to the rat ankle histology (A) Histological images of joints after tofacitinib treatment. These patterns are merely illustrative of the types of histological features observed. Black arrow indicates the absence or presence of ankle swelling in rat hind paws. C: calcaneus; E: erosion or oedema ; S: synovia; Tb: tibia; Ts: tarso. Scale bar: 100 mm. Tofacitinib suppressed inflammation and tissue damage locally in the joints of rats with adjuvant-induced arthritis. A semi-quantitative evaluation of histological sections was performed. Notice that tofacitinib inhibited cellular infiltration (B), completely reversed the number of lining layer cells to the normal values (C) and prevented the occurrence of bone erosion (D), allowing for a normal cartilage (E) and joint structure, comparable to that of healthy rats (F). Data are expressed as the median with interquartile range. Differences were considered statistically significant for P < 0.05, according to the MannWhitney U-test. Healthy: n = 20; arthritic: n = 20; tofacitinib: n = 10. tofacitinib and arthritic untreated groups. The tofacitinib group showed an increased RANKL/OPG ratio when compared with the healthy control group (P = 0.0370; Fig. 3E ).
We also quantified the circulating concentrations of IL1b, IL-6 and TNF, but no differences were found when comparing arthritic rats with animals treated with tofacitinib (Fig. 3FH) . However, there was a slight tendency for IL-6 to be diminished in the tofacitinib group when compared with untreated arthritic animals.
Tofacitinib administration significantly reduced the levels of IL-17 detected in peripheral blood (P < 0.0001, tofacitinib group vs untreated arthritic rats after 22 days of disease induction; Fig. 3I ).
Micro-CT
Arthritic rats showed a reduction in cortical bone crosssectional area (Fig. 4A) and thickness (Fig. 4B) , and tofacitinib treatment did not restore these cortical changes (P < 0.0001 vs healthy controls, respectively). These bone changes affected the torsion capability of the bone, as shown by decreased values of the polar moment of inertia (Fig. 4C) in the arthritic and tofacitinib groups (P = 0.0059 and P = 0.0197 vs healthy controls,
FIG. 3 Quantification of bone turnover markers and systemic cytokines
Serum samples collected at day 22 (sacrifice) were analysed by ELISA technique. A bone resorption marker, carboxyterminal telopeptide of type I collagen (A), and bone formation markers, procollagen type I propeptides (B), were increased in arthritic rats (P < 0.0001 and P = 0.0015, respectively). The tofacitinib group showed decreased values for carboxyterminal telopeptide of type I collagen (P = 0.0002) and procollagen type I propeptides (P = 0.0018). RANK ligand (C) and osteoprotegerin (D) were diminished in tofacitinib-treated rats when compared with arthritic untreated group (P = 0.0141 and P = 0.0002, respectively). The RANK ligand/osteoprotegerin ratio (E) showed higher values when compared with the healthy group (P = 0.0370). Tofacitinib, in this animal model, did not affect circulating concentrations of IL-1b (F) and TNF (H). The results also demonstrated a significant decrease in the serum quantification of IL-17 (I; P < 0.0001) and a tendency towards a decrease of IL-6 (G). IL-1, TNF and IL-17 were normalized. Differences were considered statistically significant for P < 0.05, according to the MannWhitney U-test. Healthy: n = 20; arthritic: n = 20; tofacitinib: n = 10. respectively). Trabecular bone also presented deterioration with arthritis, as evidenced by a reduced trabecular bone volume fraction ( Fig. 4D ; P = 0.0007 and P < 0.0001 vs healthy controls, respectively), thickness (Fig. 4E) and number ( Fig. 4F ; P < 0.0001 vs healthy controls) and also by an increased trabecular separation ( Fig. 4G ; P < 0.0001 in arthritic group and P = 0.0002 in tofacitinib group vs healthy controls) and porosity ( Fig. 4H ; P < 0.0001 vs healthy controls). Furthermore, the structure model index (Fig. 4I) showed reduced values in the arthritic and tofacitinib groups (P < 0.0001 vs healthy controls, respectively).
FIG. 4 Micro-CT analysis of samples of rat tibia
The arthritic and tofacitinib groups showed decreased values for cortical cross-sectional bone area (A), thickness (B) and polar moment of inertia (C) when compared with healthy controls. Trabecular bone also showed lower values of ratio bone volume/tissue volume (D), trabecular thickness (E) and number (F) in comparison with healthy controls. Arthritic and tofacitinib rats demonstrated higher values of trabecular separation (G) and porosity (H) when compared with healthy controls. The structural model index showed decreased values in arthritic and tofacitinib rats compared with healthy rats. Micro-CT images from tibias of healthy, arthritic untreated and tofacitinib groups (J). Images were acquired with SkyScan 1272 (Bruker microCT, Kontich, Belgium). Differences were considered statistically significant for P < 0.05, according to the MannWhitney U-test. Healthy: n = 20; arthritic: n = 20; tofacitinib: n = 10.
Tofacitinib could not rescue trabecular bone integrity and trabecular bone properties in treated rats (Fig. 4J ).
Three-point bending
As shown in Fig. 5 , arthritic rats revealed decreased mechanical properties at the yield point, namely displacement (P = 0.0192 vs healthy controls; Fig. 5A ), strength (P = 0.0229 vs healthy control; Fig. 5B ) and pre-yield energy (elastic energy; P = 0.0161 vs healthy controls; Fig. 5C ). Tofacitinib-treated rats showed a significantly decreased displacement (P = 0.0039 vs healthy controls; Fig. 5D ) and elastic properties (P = 0.0443 vs healthy controls; Fig. 5E ) at the fracture point. The results also demonstrated that arthritic and tofacitinib-treated rats had decreased maximal load (P = 0.0017 vs healthy controls; Fig. 5F ). Finally, arthritic rats and the tofacitinib-treated group showed a significant decrease in toughness (P = 0.0143 and P = 0.0048 vs healthy controls, respectively; Fig. 5G ).
Tofacitinib increased bone hardness
Arthritic rats had decreased hardness in cortical (Fig. 6A ) and trabecular bone ( Fig. 6B ; P = 0.0010 and P = 0.0080 in arthritic rats vs healthy controls, respectively). In contrast, rats treated with tofacitinib showed restored hardness in cortical bone (Fig. 6A) and increased hardness in trabecular bone ( Fig. 6B ; P = 0.0003 and P = 0.0012 vs untreated arthritic rats, respectively). No differences were observed in the other parameters analysed.
Concentric lamellae in secondary osteons (SO) were identified more frequently in arthritic animals (Fig. 6F ) than in healthy controls (P = 0.0022) and tofacitinib-treated animals (P = 0.0043; Fig. 6C ). On the contrary, healthy animals (Fig. 6E ) and tofacitinib-treated animals (Fig. 6G) presented more PL structures than concentric lamellae.
In addition, arthritic animals showed an increased area occupied by osteocyte lacunae in the total tissue, when compared with healthy and tofacitinib-treated animals ( Fig. 6D ; P = 0.0067 and P = 0.0011, respectively).
FIG. 5 Bone mechanical properties assessed by three-point bending tests in rat femur
Results showed that arthritic rats have decreased properties at the yield point, related to displacement (A), strength (B) and pre-yield energy (elastic energy; C). Tofacitinib-treated rats had a significant decrease in displacement (D) and elastic properties (E) at the fracture point. Arthritic and tofacitinib-treated bones required a lower maximal load (F) to fracture, and a decreased toughness (G) was observed. Differences were considered statistically significant for P < 0.05, according to the MannWhitney U-test. Healthy: n = 20; arthritic: n = 20; tofacitinib: n = 10.
Discussion
In this study, we showed that tofacitinib in the AIA rat model abrogated synovitis and prevented joint destruction. This was paralleled by decreased levels of IL-17, IL-6, RANKL and OPG and by a reduced bone turnover in tofacitinib-treated animals. Despite preserving bone cortical and trabecular hardness, tofacitinib did not   FIG. 6 Bone mechanical properties assessed by nanoindentation and respective topographic images Nano-mechanical tests revealed a decreased cortical (A) and trabecular (B) hardness in the arthritic group at day 22 when compared with healthy rats. Of note, rats treated with tofacitinib showed increased hardness in the cortical (A) and trabecular (B) bone in comparison with untreated arthritic rats. Results demonstrated that the number of concentric lamellae (C) and ratio of area occupied by osteocyte lacunae in the total tissue (D) were higher when compared with the healthy control and tofacitinib-treated groups at day 22. Images are merely illustrative of the types of histological features observed. Concentric lamellae were identified in SO, characteristic of arthritic animals (F). On the contrary, PL were identified in the healthy control (E) and tofacitinib-treated groups (G). Scale bar: 20 mm. Differences were considered statistically significant for P < 0.05, according to the MannWhitney U-test. Healthy: n = 20; arthritic: n = 20; tofacitinib: n = 10. CL: concentric lamellae; Os: osteocytes; PL: parallel lamellae; SO: secondary osteons.
revert the effects of arthritis on cortical and trabecular bone structure and on mechanical properties.
These results are in line with the pre-clinical and clinical evidence regarding the efficacy of tofacitinib in controlling clinical manifestations of RA and preventing joint damage [11, 2529] . However, the effects of tofacitinib on the systemic bone fragility of patients affected by RA are still unknown, and thus, the results of this exploratory animal study can contribute to a better understanding of the effect on bone of JAKSTAT inhibition.
At the tissue level, measured by nanoindentation, tofacitinib treatment conserved bone hardness (or even increased in the case of the trabecular component). We also observed, at days 11 and 22 after induction of arthritis, concentric lamellae in SO microstructures resulting from high bone remodelling, as previously described [15, 30, 31] . Dall'Ara et al. [31] suggested that larger numbers of these younger, less mineralized and less hard structures could be related to reduced hardness of bone tissue identified by nanoindentation. On the contrary, healthy and tofacitinib-treated animals presented more PL structures than concentric lamellae in SO structures, PL structures which represents the mature bone structure (and normal bone remodelling) are 10% harder than the concentric lamella structure. [31] . In addition, arthritic animals had an increased area occupied by osteocyte lacunae in the total tissue. Tofacitinib-treated animals, in contrast, had a normal number of osteocyte lacunae and of the lacunar area per tissue volume. Osteocytes are responsible for the maintenance of bone homeostasis, regulating the behaviour of osteoblasts and osteoclasts by communicating through gap junctions [32] . Studies have revealed that osteocytes from OA patients have an irregular morphology, with limited ability to respond to mechanical stimuli, leading to significant changes in the structure and mineral density [33] . Despite still being unclear, this apparent change of osteocyte morphology in arthritic bone might contribute to the nanomechanical changes observed in this context.
Micro-CT and three-point bending tests revealed that tofacitinib did not revert the effects of arthritis on cortical and trabecular bone structure and mechanical properties. There are several possible explanations for these observations. Using the same animal model, we were able to revert the structural and mechanical damage induced by arthritis using an experimental compound [18] . However, the kinetics of the effects of tofacitinib might be different, needing more exposure time to have an impact on bone quality. The effect at a tissue level might be an early sign of its delayed impact on bone. Of interest, an increase in hardness is associated with a decrease in the relative ratio of elasticto-plastic behaviour of the tissue, and thus, it is unclear whether it ultimately represents a true improvement in mechanical properties. Another explanation might be related to the mechanism of action. Tofacitinib targets JAK1 and JAK3, downregulating STAT1 and STAT3 of the JAKSTAT signalling pathway [11, 12, 25] , and these intracellular molecules have complex interactions with bone. JAK1 is expressed in bone cells and is involved in bone formation. The depletion of JAK1 promotes a delay in bone growth, suggesting that JAK1 is crucial for skeletal development. In contrast, in osteoblasts STAT1 inhibits transcription of Runx2, the master transcription factor of osteoblast differentiation. Thus, STAT1 is an inhibitor of differentiation of osteoblasts, and the inactivation of STAT1 leads to an osteopetrotic bone phenotype [34] . Consistent with the higher bone mass in STAT1-deficient mice, inactivation of STAT1 can accelerate fracture repair [35] . These data suggest that STAT1 negatively regulates bone formation in vivo [36] . On the contrary, the JAKSTAT3 signal transduction pathway promotes osteoblast differentiation [36] . In fact, inactivation of STAT3 in osteoblasts leads to lower bone mass attributable to inhibition of bone formation, and STAT3 mutations increase osteoclast number and bone resorption and are associated with recurrent fractures. It is conceivable that these types of molecular interactions with bone have an overall effect that might not be totally compensated by the benefits obtained by the control of inflammation.
Broad, unspecific molecular effects of MTX potentiate the effect of targeted therapies. This is expected to occur in the combination of MTX with tofacitinib and might contribute, as already explored in clinical trials, to an increment in inflammatory control, probably fully compensating bone damage [37] . To clarify these open questions it will be relevant to test several doses of tofacitinib and also combination therapy with MTX, in longer duration arthritis models and in healthy animals. In addition, the discrepancy between the effect of tofacitinib on joint erosions and on skeletal bone deserves a full microstructural study of intra-articular bone compared with skeletal bone.
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